IP Library › Granted Patent US 12,492,411
Granted Patent B2
US 12,492,411 · App. 17/059,193 · Granted Dec 9, 2025

Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA)

Inventors: Donald B. Kohn (Tarzana, CA); Caroline Y. Kuo (Beverly Hills, CA); David Gray (San Diego, CA); Zulema Romero Garcia (Los Angeles, CA); Roger P. Hollis (Los Angeles, CA); Anastasia Lomova (Tarzana, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C12N15/86A61K38/1793A61K40/11A61K40/40A61K48/0066A61P37/04C12N5/0636C12N9/22C12N15/11C12N15/907C12N2310/14C12N2310/20C12N2740/15043C12N2750/14143C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,411
App. No.
17/059,193
Granted
Dec 9, 2025
Kind
B2
Abstract

In certain embodiments methods of treating X-Linked agammaglobulinemia (XLA) in a mammal are provided where the methods comprise: i) providing differentiated T cells and/or stem/progenitor cells from the mammal; ii) performing a targeted insertion of a corrective BTK cDNA at the BTK gene locus in said cells to provide a corrected BTK gene in said cells; and iii) introducing said cells into said mammal where said corrected BTK gene is expressed in a physiologically regulated manner.

Claims (46)

1 . A method of treating X-Linked agammaglobulinemia (XLA) in a mammal, said method comprising:

providing differentiated T cells and/or stem/progenitor cells from said mammal;

performing a targeted insertion of a corrective copy of a BTK cDNA at the BTK gene locus in said cells to provide a corrected BTK gene, wherein said corrective BTK cDNA comprises a sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, and wherein said targeted insertion places said BTK cDNA in BTK exon 1, BTK intron 1, or BTK exon 2, downstream and operably linked to the endogenous BTK enhancer/promoter; and

introducing said modified cells into said mammal where said corrected BTK gene is expressed in a physiologically regulated manner.

2 . The method of claim 1 , wherein said performing a targeted insertion comprises:

transducing said cells with an AAV vector or integrase defective lentiviral vector (IDLV) containing a donor comprising said corrective BTK cDNA flanked by homology arms; and

transfecting said cells in vitro, with:

a TALEN protein or a TALEN mRNA targeting the BTK gene; or

a nucleic acid encoding a guide RNA (gRNA) and CRISPR/Cas endonuclease where said gRNA targets the BTK gene; or

a ribonucleoprotein (RNP) complex comping a guide RNA complexed to a CRISPR/Cas endonuclease, where said gRNA targets the BTK gene.

3 . The method of claim 2 , wherein:

said BTK cDNA donor sequence is flanked by a 5′ homology arm that begins at the TALEN or CRISPR/Cas cut site and extends at least 50 bp upstream, or at least 100 bp upstream, or at least 200 bp upstream, or at least 300 bp upstream, or at least 400 bp upstream, or at least 500 bp upstream; and/or

said BTK cDNA donor sequence is flanked by a 5′ homology arm that begins at the TALEN or CRISPR/Cas cut site and extends about 500 bp upstream from said site; and/or

said cDNA donor sequence is flanked by a 3′ homology arm that extends at least 50 bp, or at least 100 bp, or at least 200 bp, or at least 300 bp, or at least 350 bp, or at least 400 bp, or at least 450 bp, or at least 500 bp downstream of the TALEN or CRISPR/Cas cut site; and/or

said BTK cDNA donor sequence is flanked by a 3′ homology arm that extends at about 500 bp downstream of the TALEN or CRISPR/Cas cut site.

4 . The method of claim 1 , wherein:

said cDNA donor is codon-optimized/-divergent; and/or

said cDNA donor is modified to exclude protospacer adjacent motifs (PAMs); and/or

said cDNA is modified by modifying a PAM sequence TGG to TAA.

5 . The method of claim 1 , wherein:

said method comprises transducing said differentiated T cells and/or stem/progenitor cells with the integrase defective lentiviral vector (IDLV) containing said corrective BTK cDNA flanked by homology arms; and/or

said method comprises transducing said differentiated T cells and/or stem/progenitor cells with an AAV vector containing a corrective BTK cDNA flanked by homology arms.

6 . The method of claim 5 , wherein said AAV vector comprises a serotype selected from the group consisting of AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, and AAV9.

7 . The method of claim 5 , wherein:

a helper protein is introduced into said cells; and/or

a helper protein is introduced into said cells wherein said helper protein comprises a mutant adenoviral serotype 5 helper protein; and/or

a helper protein is introduced into said cells wherein said helper proteins comprise E4orf6 and/or E1b55k helper proteins.

8 . The method of claim 7 , wherein:

said method comprises transfecting said cells in vitro, with TALEN mRNA targeting exon 1, intron 1, or exon 2 of the BTK gene; or

said method comprises transfecting said cells in vitro, with a nucleic acid encoding a guide RNA (gRNA) and CRISPR/Cas endonuclease where said gRNA targets exon 1, intron 1, or exon 2 of the BTK gene.

9 . The method of claim 1 , wherein:

said method comprises transfecting said cells in vitro, with a ribonucleoprotein (RNP) complex comprising a guide RNA (gRNA) complexed to a CRISPR/Cas endonuclease, where said gRNA targets a site in BTK exon 1; or

said method comprises transfecting said cells in vitro, with a ribonucleoprotein (RNP) complex comprising a guide RNA (gRNA) complexed to a CRISPR/Cas endonuclease, where said gRNA targets a site in BTK exon 1 comprising the sequence of SEQ ID NO: 1; or

said method comprises transfecting said cells in vitro, with a ribonucleoprotein (RNP) complex comprising a guide RNA (gRNA) complexed to a CRISPR/Cas endonuclease, where said gRNA targets a site in BTK intron 1; or

said method comprises transfecting said cells in vitro, with a ribonucleoprotein (RNP) complex comprising a guide RNA (gRNA) complexed to a CRISPR/Cas endonuclease, where said gRNA targets a site in BTK intron 1 comprising the sequence of SEQ ID NO:3).

10 . The method of claim 9 , wherein the CRISPR/Cas endonuclease is a Cas9 polypeptide and the corresponding CRISPR/Cas guide RNA is a Cas9 guide RNA.

11 . The method of claim 1 , wherein:

said method comprises transfecting said cells in vitro, with a ribonucleoprotein (RNP) complex comprising a guide RNA (gRNA) complexed to a CRISPR/Cas endonuclease, where said gRNA targets a site in BTK exon 2; or

said method comprises transfecting said cells in vitro, with a ribonucleoprotein (RNP) complex comprising a guide RNA (gRNA) complexed to a CRISPR/Cas endonuclease, where said gRNA targets a site in BTK exon 2 comprising the sequence of SEQ ID NO: 8.

12 . The method of claim 1 , wherein:

said cells comprise hematopoietic stem and progenitor cells (HSPC); and/or

said cells comprise CD34+ hematopoietic stem and progenitor cells (HSPC); and/or

said cells comprise peripheral blood stem cells (PBSC); and/or

said cells comprise G-CSF mobilized peripheral blood stem cells (PBSC); and/or

said cells comprise CD34+ cells.

13 . The method of claim 1 , wherein said method provides at least 3%, or at least 4%, or at least 5%, or at least 6%, or at least 7%, or at least 8%, or at least 9%, or at least 10% corrected hematopoietic stem cells with functional BTK.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2025
From: KOHN, DONALD B.; KUO, CAROLINE Y.; GRAY, DAVID; GARCIA, ZULEMA ROMERO; HOLLIS, ROGER P.; LOMOVA, ANASTASIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 072606/0994 →
Continuity (3)
Provisional Application 62760448 · Nov 13, 2018
Provisional Application 62678218 · May 30, 2018
Related Publication 20210379105A1 · Dec 9, 2021
References Cited (68)
US 3106831A · Behrens · 1963 [cited by applicant]
US 6106832A · Spriggs et al. · 2000 [cited by applicant]
US 20090054985A1 · Anderson · 2009 [cited by applicant]
US 20160208243A1 · Zhang et al. · 2016 [cited by applicant]
US 20170101641A1 · Vorechovsky et al. · 2017 [cited by applicant]
US 20170121693A1 · Liu et al. · 2017 [cited by applicant]
US 20170335011A1 · Conklin et al. · 2017 [cited by applicant]
US 20180002719A1 · Roeth et al. · 2018 [cited by applicant]
US 20200325458A1 · Rawlings et al. · 2020 [cited by applicant]
US 20210324381A1 · Rawlings et al. · 2021 [cited by applicant]
US 20230158110A1 · Kuo et al. · 2023 [cited by applicant]
GB 2338237 · 1999 [cited by applicant]
WO WO2002077227 · 2002 [cited by applicant]
WO WO2016182959A1 · 2016 [cited by applicant]
WO WO2016186772A2 · 2016 [cited by applicant]
WO WO2016201047A1 · 2016 [cited by examiner]
WO WO2017053729A1 · 2017 [cited by applicant]
WO WO2017143071A1 · 2017 [cited by applicant]
WO WO2018232356A1 · 2018 [cited by applicant]
WO WO2019084168A1 · 2019 [cited by applicant]
WO WO2019210216A2 · 2019 [cited by applicant]
WO WO2019232251A1 · 2019 [cited by applicant]
WO WO2019232253A1 · 2019 [cited by applicant]
Aria, et al., Journal of Human Genetics (2011) 56, 577-582 (Year: 2011). [cited by examiner]
(Gundry et al., Experimental Hematology (2017) 54: 4-11 (Year: 2017). [cited by examiner]
Clough, C. et al., “132. Targeting the BTK Locus in Primary Human Hematopoietic Cells with TALENs and AAV Donor Template”, Molecular Therapy, May 1, 2016, vol. 24, No. Suppl. 1, pp. S54. [cited by applicant]
Dye, M.J., “Terminal Exon Definition Occurs Cotranscriptionally and Promotes Termination of RNA Polymerase II,” Molecular Cell, Mar. 1999, vol. 3, pp. 371-378. [cited by applicant]
EP Search Report dated Feb. 23, 2022, in Application No. EP19812414.1. [cited by applicant]
Extended European Search Report dated Apr. 25, 2022, in Application No. EP19810629.6. [cited by applicant]
Hermaszewski, R.A ., & Webster, A.D.B., “Primary Hypogammaglobulinaemia: a Survey of Clinical Manifestations and Complications,” QJM: An International Journal of Medicine, Jan. 1993, vol. 86(1), pp. 31-42. [cited by applicant]
Hubbard, N. et al., “Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome”, Blood, May 26, 2016, vol. 127, No. 21, pp. 2513-2522. [cited by applicant]
International Preliminary Report on Patentability dated Dec. 10, 2020 in PCT Application No. PCT/US2019/034713. [cited by applicant]
International Preliminary Report on Patentability dated Dec. 10, 2020 in PCT Application No. PCT/US2019/034715. [cited by applicant]
International Search Report and Written Opinion dated Oct. 9, 2019 in PCT Application No. PCT/US2019/034713. [cited by applicant]
International Search Report and Written Opinion dated Oct. 18, 2019 in PCT Application No. PCT/US2019/034715. [cited by applicant]
Kohn, D.B. et al., “New Frontiers in the Therapy of Primary Immunodeficiency: From Gene Addition to Gene Editing”, The Journal of allergy and clinical immunology, Mar. 2017, vol. 139, No. 3, pp. 726-732. [cited by applicant]
Kuo, C.Y. et al., “Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome”, Cell reports, May 29, 2018, vol. 23, No. 9, pp. 2606-2616. [cited by applicant]
Kuo, C.Y., et al., “Targeted Gene Therapy in the Treatment of X-linked Hyper-IgM Syndrome,” Gene Targeting and Gene Correction I,May 2014, vol. 22(1), p. S36. [cited by applicant]
Ng. Y.Y. et al., “Correction of B-cell Development in Btk-deficient Mice Using Lentiviral Vectors With Codon-optimized Human BTK”, Leukemia, 2010, vol. 24, pp. 1617-1630. [cited by applicant]
Ravin, S.S.De., et al., “Lentiviral Hematopoietic Stem Cell Gene Therapy for X-linked Severe Combined Immunodeficiency,” Science translational medicine, Apr. 20, 2016, vol. 8(335): 33ra57, 12 pages. [cited by applicant]
Seyama, K. et al., “Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome”, Blood, Oct. 1, 1998, vol. 92, No. 7, pp. 2421-2434. [cited by applicant]
Shaul, O., “How Introns Enhance Gene Expression,” The international journal of biochemistry & cell biology, Oct. 2017, vol. 9(Pt B), pp. 145-155. [cited by applicant]
Siegal, F.P, et al., “Lymphocytes in Human Immunodeficiency States: a Study of Membrane-associated Immunoglobulins,” European Journal of Immunology, 1971, vol. 1(6), pp. 482-486. [cited by applicant]
Tsukada, S., et al., “Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-linked Agammaglobulinemia,” Cell, Jan. 29, 1993, vol. 279-290. [cited by applicant]
Brown et al., “Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice”, Nature Medicine, Nov. 1998; 4(11): 1253-1260. [cited by applicant]
De La Morena, et al., “Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantations”, Journal of Allergy and Clinical Immunology, Apr. 2017; 139(4):1282… [cited by applicant]
Dull et al., “A third-generation lentivirus vector with a conditional packaging system”, Journal of Virology, Nov. 1998, 72(11): 8463-8471. [cited by applicant]
Ebina et al., “Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus”, Scientific Reports, Aug. 26, 2013; 3: 2510. [cited by applicant]
Gennery et al., “Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002”, Blood, Oct. 2, 2003; 103(3):1152-1157. [cited by applicant]
Hayward et al., “Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-Ig,M”, Journal of Immunology, Jan. 15, 1997; 158(2): 977-983. [cited by applicant]
Hollenbaugh et al., “The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1”, The Journal of Clinical Investigation, Aug. … [cited by applicant]
Hu et. al., “Heritable gene-targeting with gRNA/Cas9 in rats”, Cell Research, Oct. 22, 2013;23:1322-1325. [cited by applicant]
Levy et al., “Clinical spectrum of X-linked hyper-IgM syndrome”, The Journal of Pediatrics, Jul. 1997; 131(1): 47-54. [cited by applicant]
Mitsui-Sekinaka et al., “Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan”, Journal of Allergy and Clinical Immunology, Mar. 31, 2015; 136(4): 1018-1024. [cited by applicant]
Saifuddin et al., “Phosphorylation and the regulation of CD40L mRNA stability by polypyrimidine tract binding protein (P1394)”, J. Immunol., May 1, 2013; 190(1_Supplement): 203.14. [cited by applicant]
Tsai et al., “GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases”, Nat. Biotechnol., Feb. 2015; 33(2):187-197. doi: 10.1038/nbt.3117. [cited by applicant]
Zufferey et al., “Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery”, Journal of Virology, Dec. 1998; 72(12): 9873-9880. [cited by applicant]
Follenzi et al., “Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences”, Nature Genetics, Jun. 2000; 25: 217-222. [cited by applicant]
Genome assembly GRCh37.p13. National Library of Medicine (accessed at: https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001405.25/) (Year: 2013). [cited by applicant]
Liu et al., “Biallelic insertion of a transcriptional terminator via the CRISPR/Cas9 system efficiently silences expression of protein-coding and non-coding RNA genes”, J Biol Chern. Feb. 14, 2017; 292(14):5624-5633. [cited by applicant]
Barrett et al., “Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements”, Cell Mol Life Sci. Nov. 2012; 69(21):3613-34. Epub Apr. 27, 2012. [cited by applicant]
Leppek et al., “Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them”, Nat Rev Mol Cell Biol. Mar. 2018; 19(3):158-174. Epub Nov. 22, 2017. [cited by applicant]
Clerte et al., “The domains of polypyrimidine tract binding protein have distinct RNA structural preferences”, Biochemistry, Mar. 17, 2009; 48(10):2063-2074. [cited by applicant]
Rohrer et al., “Correction of X-Linked Immunodeficient Mice by Competitive Reconstitution With Limiting Numbers of Normal Bone Marrow Cells”, Blood, Nov. 15, 1999; 94(10):3358-3365. [cited by applicant]
Rohrer et al., “Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions”, Clinical Immunology, Jan. 1999; 90(1): 28-37. [cited by applicant]
Naldini et al., “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector”, Proceedings of the National Academy of Sciences, Oct. 1996; 9… [cited by applicant]
Sather et al., “Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders”, Molecular Therapy, Nov. 2011; 19(3): 515-525. [cited by applicant]
Mohamed et al., “Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain”, Immunol. Rev. (2009) 228: 58-73. [cited by applicant]